Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (3)
  • Necroptosis
    (1)
  • Parasite
    (1)
  • RIP kinase
    (1)
  • Virus Protease
    (1)
  • Others
    (5)
Filter
Search Result
Results for "

lc3-ii

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
Retro-2
Retro 2, 2-{[(5-methyl-2-thienyl)methylene]amino}
T89031201652-50-7
Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Autophagy-IN-6
T200952
Autophagy-IN-6 (compound 1u) is an inhibitor of lysosomal autophagy that induces the accumulation of the LC3-II protein. Additionally, it exhibits antiproliferative activity.
  • Inquiry Price
Size
QTY
RIP3 activator 1
T2016771456899-52-7
RIP3 Activator 1 (compound C8) is an effective RIP3 activator that inhibits cell growth and induces necroptotic cell death (necroptosis) and autophagy through the RIP3 p62 Keap1 signaling pathway. Additionally, this compound enhances the expression of p-MLKL and promotes the accumulation of LC3-II and p62 proteins.
  • Inquiry Price
10-14 weeks
Size
QTY
DK-1-49
T27187853136-76-2
DK-1-49 is an autophagonizer. It causes accumulation of autophagy-associated LC3-II and enhanced levels of autophagosomes and acidic vacuoles.
  • Inquiry Price
6-8 weeks
Size
QTY
Quinacrine analog 34
T357471411646-44-0
Quinacrine is a compound with multiple actions that is commonly used as an anti-protozoal agent. It has also been shown to be a highly potent autophagy inhibitor, although the dose required to achieve this effect is considerably cytotoxic (LD50 = 2.5 μM). Quinacrine analog 34 is a derivative of quinacrine that was designed with an improved cell viability profile (LD50 = 27 μM) to inhibit autophagy. At a minimum concentration of 0.5 μM, this compound has been shown to increase the protein levels of the autophagy biomarker LC3-II and to induce lysosome deacidification.
  • Inquiry Price
6-8 weeks
Size
QTY
TrxR-IN-3
T604532445565-58-0
TrxR-IN-3 (Compound 2c) is an effective TrxR inhibitor that exhibits strong antiproliferative activities against five human cancer cell lines, particularly breast tumor cells. It increases ROS levels, induces apoptosis by regulating apoptosis-related protein expression in breast cancer cells, and promotes autophagosome and autolysosome formation by enhancing LC3-II and Beclin-1 expression and reducing LC3-I and p62 protein expression [1].
  • Inquiry Price
6-8 weeks
Size
QTY
ac-leu-val-lys-aldehyde
T76599147600-40-6
Ac-Leu-Val-Lys-Aldehyde is a potent inhibitor of cathepsin B, with an inhibitory concentration (IC50) of 4 nM. It significantly reduces quinolinic acid-induced cell death in the striatum and results in the accumulation of LC3-II [1].
  • Inquiry Price
Size
QTY
Dendrogenin A
​DDA
T837651191043-85-2
Dendrogenin A (DDA) is a compound acting as a selective liver X receptor (LXR) modulator, cholesterol epoxide hydrolase inhibitor (Ki = 120 nM), and a metabolic product of cholesterol, originating from 5,6α-epoxy cholesterol through histamine conjugation via DDA synthase. This compound is present in non-cancerous human mammary epithelial cells and melanocytes, but absent or minimally present in various breast carcinoma, melanoma cells, and isolated human breast tumor tissues. DDA impedes the activation of LXRβ and LXRα induced by 22(R)-hydroxy cholesterol (IC50s = 76 and 362 nM, respectively), yet it also functions as a partial LXR agonist, boosting the protein levels of Nur77, NOR-1, LC3-I, and LC3-II in B16/F10 murine melanoma cells. It shows a preference for LXRα and LXRβ modulation while displaying selectivity over other receptors including pregnane X receptor (PXR), and various others at a concentration of 2.5 µM. Moreover, DDA enhances LC3-II protein levels in cancer cells and prompts autophagic cell death at specific concentrations. Notably, DDA (0.37 µg/kg) has been shown to diminish tumor growth in melanoma and mammary cancer murine models and promotes cancer cell differentiation both in vitro and in vivo.
  • Inquiry Price
8-10 weeks
Size
QTY